Medicenna Therapeutics Corp

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update